Home / Blog / FDA Approves Drug for Pancreatic Cancer Treatment

FDA Approves Drug for Pancreatic Cancer Treatment

FDA Approves Drug for Pancreatic Cancer Treatment

Dec. 30, 2019 — There’s a brand new remedy possibility for some sufferers with pancreatic most cancers — those that lift a selected genetic mutation can now be handled with the drug olaparib (Lynparza).

The FDA licensed olaparib for use as a first-line remedy of most cancers that has grown past the pancreas in sufferers with what’s referred to as a germline BRCA mutation.

Olaparib is already licensed for use in BRCA-mutated ovarian and breast cancers.

But there are a number of different therapies for those two most cancers varieties, while there are few choices for pancreatic most cancers. It’s some of the devastating cancers — survival charges are the bottom of the most typical most cancers varieties. (The Five-year survival fee is handiest 2% to nine%.)

“Metastatic pancreatic most cancers sufferers had been ready a very long time for new remedy choices for their devastating illness,” stated Julie Fleshman, president and CEO of Pancreatic Cancer Action Network, a affected person reinforce staff.

“Today’s approval of olaparib provides an exciting new treatment option for patients with germline BRCA-mutated metastatic pancreatic cancer,” she stated in a observation.

About four% to nine% of people that have metastatic pancreatic most cancers are concept to hold the BRCA mutation.



Medscape Medical News


© 2019 WebMD, LLC. All rights reserved.

Check Also

What are your tips & tricks on playing with color on the eyes?

What are your tips & tricks on playing with color on the eyes? Comments that …

Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: